1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNew York State Biodefense Commercialization Fund is sponsored by Empire State Development (New York State Urban Development Corporation d/b/a Empire State Development). This opportunity supports mission-aligned projects and measurable outcomes.
Get alerted about grants like this
Save a search for “Empire State Development (New York State Urban Development Corporation d/b/a Empire State Development)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
powered by LeadingAge New York Assisted Living and Adult Care Facilities Continuing Care Retirement Communities Federal Budget and Policy Actions Infectious Disease Resources Workforce Issues and Regulations State Councils and Task Forces Diversity, Equity, and Inclusion LeadingAge Quality Metrics LeadingAge New York FASTracker Value First Group Purchasing LeadingAge New York Business Partners LeadingAge New York Consumer Guide Sponsorships & Partner Packages 2025 Membership Directory Current Grants and Grant Opportunities New York State has launched Round XIII of the Regional Economic Development Council (REDC) Initiative.
Round XIII includes core capital grant and tax-credit funding combined with a wide range of programs from multiple state agencies. Entities seeking funding for projects that would advance the priorities of their REDC are encouraged to apply using the New York State Consolidated Funding Application (CFA), a single application for multiple sources of state funding.
While many of the targeted economic development programs may not apply to members, two Empire State Development (ESD) Capital Grant programs may offer an opportunity.
Examples of eligible costs include, but are not limited to: Acquisition of land, buildings, furniture, fixtures, machinery, and/or equipment; New construction, renovation, or leasehold improvements; Infrastructure improvements to the facility; Compliance with Americans with Disabilities Act (ADA) accessibility requirements; or Other capital costs/expenditures deemed eligible by ESD.
The deadline to apply through the CFA for most of the programs, including the NFP Capital Grant Program, is 4 p. m. on Fri.
, July 28, 2023. Information on the main ESD Capital Grants program that will provide $150 million this round to a wider applicant pool than the NFP program and that accepts applications on an ongoing basis (i.e., is not subject to the July 28 th deadline) is available here .
It is designed for capital-based economic development projects intended to create or retain jobs; prevent, reduce, or eliminate unemployment and underemployment; and/or increase business or economic activity in a community or region. This year’s strategic focus areas include green buildings and child care projects. A press release with an overview of Round XIII is here .
The REDC website with resources and complete information on all of the funding programs and application materials is here . Contact: Darius Kirstein, dkirstein@leadingageny. org , 518-867-8841 13 British American Blvd Suite 2 LeadingAge NY Services Inc. Foundation for Long Term Care Adult Day Health Care Council
Based on current listing details, eligibility includes: Incorporated Startup Companies and Academic Institutions. Startup and early-stage companies based in New York that have raised Seed, Series A, or Series B funding are eligible. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Startup Companies: $1 million to $4 million; Academic Institutions: $250,000 to $500,000. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.